Intraperitoneal_hemorrhage_from_hepatocellular_carcinoma:_emergency_chemoembolization_or_embolization._From_1982_to_1990,_38_patients_with_intraperitoneal_hemorrhage_from_hepatocellular_carcinoma_(HCC)_underwent_treatment_with_emergency_embolization_with_or_without_anticancer_drug_and_iodized_oil._Before_emergency_embolization,_24_patients_had_a_serum_total_bilirubin_value_of_3.0_mg/dL_or_less_(group_A)_and_14_patients_had_hyperbilirubinemia,_with_a_serum_bilirubin_level_greater_than_3.0_mg/dL_(group_B)._Successful_hemostasis_was_achieved_in_all_patients._The_mean_length_of_survival_was_165_days_in_group_A_and_13_days_in_group_B._A_significant_correlation_(P_less_than_.00003)_between_serum_bilirubin_level_and_prognosis_was_obtained._While_tumor_thrombus_in_the_portal_vein_made_the_prognosis_poor,_there_was_no_significant_difference_in_prognosis_between_groups_with_and_without_tumor_thrombus_(P_=_.145)._Emergency_embolization_is_an_effective_treatment_in_patients_with_intraperitoneal_hemorrhage_from_HCC._The_prognosis_for_patients_with_HCC_depends_on_the_serum_bilirubin_level_before_embolization.